Two recent, peer-reviewed clinical studies have found that Almased, a high-protein, low-glycemic meal replacement, delivers significant health benefits ranging from weight loss and improved metabolic health to anti-aging effects and enhanced quality of life. Both reviews synthesize 30 peer-reviewed clinical studies across three decades of scientific research, confirming that Almased is effective and safe for weight reduction, preservation of lean muscle mass, and cardiovascular health. The ...

Ant Group today launched its AI healthcare app, AQ, to accelerate the company’s entry into the healthcare sector. The app helps users manage their daily healthcare needs with over 100 AI-powered services, including doctor recommendations, medical report analysis, and personalized medical advice. It also connects users to digital services from over 5,000 hospitals and nearly 1 million doctors across China. This press release features multimedia. View the full release here: https://www.businessw...

BlueSnap, a global payment orchestration platform for leading B2B and B2C businesses, announced its selection by FlightLogger as its international payments partner, unlocking global payments capabilities and greater financial flexibility and acceptance for pilots in training. As a leading flight training management software company, FlightLogger – backed by leading private equity company Arcadea Group – helps 200 flight schools across more than 50 countries optimize their pilot training workf...

Intelligent power management company Eaton announced today it was awarded multiple contracts valued at approximately $25 million to help Hartsfield-Jackson Atlanta International Airport enhance and expand its electrical infrastructure. Eaton is providing comprehensive engineering services and electrical solutions to support the airport’s broader modernization efforts – establishing a resilient energy backbone with the real-time data and intelligent tools needed to optimize energy efficiency, ac...

Not intended for UK-, US- or Canada-based media Merck, a leading science and technology company, today announced the presentation of detailed results from Cohort B of the global Phase 2 WILLOW study (NCT05162586) evaluating enpatoran, an investigational, oral, novel TLR7/8 inhibitor in systemic lupus erythematosus (SLE). Although it did not meet the primary endpoint of dose-response relationship, when compared to placebo, enpatoran demonstrated improvements in measures of both systemic and cu...